Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000553517 | SCV000628520 | benign | Neurofibromatosis, type 1 | 2024-11-26 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001799676 | SCV002044239 | uncertain significance | not provided | 2024-02-07 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 25486365, 2121369, 22807134) |
Genome- |
RCV000553517 | SCV002560295 | uncertain significance | Neurofibromatosis, type 1 | 2022-03-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002456062 | SCV002615554 | uncertain significance | Hereditary cancer-predisposing syndrome; Cardiovascular phenotype | 2023-02-15 | criteria provided, single submitter | clinical testing | The p.H1143R variant (also known as c.3428A>G), located in coding exon 26 of the NF1 gene, results from an A to G substitution at nucleotide position 3428. The histidine at codon 1143 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |